![VERDI Study (VERifynow in Diabetes non-responsiveness: a study on switching from Clopidogrel to Prasugrel). A randomized, mono-center study comparing the treatment plan of a loading dose of prasugrel as opposed to the standard dose in type 2 diabetic patients, who suffer acute coronary syndrome, revascularized through an invasive percutaneous strategy with a stent. [Estudio aleatorizado, unicentrico, que compara un regimen de dosis de carga de prasugrel (60 mg) y posterior dosis de mantenimiento (10 mg) frente al regimen con dosis estandar de clopidogrel (75 mg) en pacientes diabeticos tipo 2 no respondedores a clopidogrel revascularizados mediante una estrategia invasiva percutanea con stent farmacoactivo.]](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "VERDI Study (VERifynow in Diabetes non-responsiveness: a study on switching from Clopidogrel to Prasugrel). A randomized, mono-center study comparing the treatment plan of a loading dose of prasugrel as opposed to the standard dose in type 2 diabetic patients, who suffer acute coronary syndrome, revascularized through an invasive percutaneous strategy with a stent. [Estudio aleatorizado, unicentrico, que compara un regimen de dosis de carga de prasugrel (60 mg) y posterior dosis de mantenimiento (10 mg) frente al regimen con dosis estandar de clopidogrel (75 mg) en pacientes diabeticos tipo 2 no respondedores a clopidogrel revascularizados mediante una estrategia invasiva percutanea con stent farmacoactivo.]"){kind=logo}
Trial Profile
VERDI Study (VERifynow in Diabetes non-responsiveness: a study on switching from Clopidogrel to Prasugrel). A randomized, mono-center study comparing the treatment plan of a loading dose of prasugrel as opposed to the standard dose in type 2 diabetic patients, who suffer acute coronary syndrome, revascularized through an invasive percutaneous strategy with a stent. [Estudio aleatorizado, unicentrico, que compara un regimen de dosis de carga de prasugrel (60 mg) y posterior dosis de mantenimiento (10 mg) frente al regimen con dosis estandar de clopidogrel (75 mg) en pacientes diabeticos tipo 2 no respondedores a clopidogrel revascularizados mediante una estrategia invasiva percutanea con stent farmacoactivo.]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2016
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Thromboembolism
- Focus Therapeutic Use
- Acronyms VERDI
- 01 Dec 2015 Results published in the Acta Cardiologica
- 12 Sep 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01684813).
- 12 Sep 2012 Planned number of patients changed from 50 to 65 as reported by ClinicalTrials.gov.